Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals

Drugs

Volumn 72, Issue 2, 2012, Pages 217-228

  Tetrault, Jeanette M ^a   Fiellin, David A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesics; Buprenorphine; Heroin abuse; Methadone; Naltrexone; Opioid abuse; Opioid analgesics

Indexed keywords

ATAZANAVIR; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; DARUNAVIR; DIAMORPHINE; EFAVIRENZ; FLUCONAZOLE; HYPERICUM PERFORATUM EXTRACT; LEVACETYLMETHADOL; METHADONE; NALOXONE; NALTREXONE; NEVIRAPINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; PLACEBO; RIFAMPICIN; VORICONAZOLE; ZIDOVUDINE;

BONE DENSITY; CONSTIPATION; DROWSINESS; DRUG BINDING; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG MISUSE; DRUG OVERDOSE; DRUG POTENTIATION; FOLLOW UP; HEROIN DEPENDENCE; HUMAN; HYPOGONADISM; INFECTION; PLUS NALOXONE; LIBIDO; MAINTENANCE THERAPY; METHADONE TREATMENT; OPIATE ADDICTION; OPIATE ADDICTION; PLUS NALOXONE; PREVALENCE; QT PROLONGATION; REVIEW; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; SWEATING; THERAPY EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D BLOOD LEVEL;

ANALGESICS, OPIOID; HUMANS; NARCOTIC ANTAGONISTS; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

HEPATITIS C VIRUS;

EID: 84856084883     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11597520-000000000-00000     Document Type: Review

References (88)

1. Diagnostic and statistical manual of mental disorders fourth edition. DSM-IV. Washington, DC: American Psychiatric Association, 1994
2. Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006; 43 Suppl. 4: S173-7 (Pubitemid 44901884)
3. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press, 2009
4. Substance Abuse and Mental Health Services Association. Results from the 2009 National Survey on Drug Use and Health, Rockville (MD): Department of Health and Human Services, 2009
5. Fiellin DA, O'Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002; 137 (8): 688-92 (Pubitemid 35176103)
6. Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349 (10): 975-86
7. Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997; 7 (5): 713-9 (Pubitemid 27500834)
8. Nestler EJ, Bergson CM, Gultart X, et al. Regulation of neural gene expression in opiate and cocaine addiction. NIDA Res Monogr 1993; 125: 92-116 (Pubitemid 24088782)
9. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348 (18): 1786-95 (Pubitemid 36514710)
10. O'Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294 (8): 961-3 (Pubitemid 41215467)
11. Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database System Rev 2004; (4): CD005031
12. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquire Immune Defic Syndr 1993; 6 (9): 1049-56 (Pubitemid 23239778)
13. Metzger DS, Woody GE, O'Brien CP. Drug treatment as HIV prevention: a research update. J Acquire Immune Defic Syndr 2010; 55 Suppl. 1: S32-6
14. Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Substance Abuse Treat 2008; 35 (1): 87-92 (Pubitemid 351734596)
15. Lobmaier P, Gossop M, Waal H, et al. The pharmacological treatment of opioid addiction: a clinical perspective. Eur J Clin Pharmacol 2010; 66 (6): 537-45
16. McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269 (15): 1953-9 (Pubitemid 23106867)
17. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011 Oct 5; (10): CD004147
18. Stine SM, Kosten TR. Pharmacologic interventions for opioid dependence, in principles of addiction medicine. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2010: 651-69
19. Dole VP. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 646-50
20. Dole VP. Narcotic addiction, physical dependence and relapse. N Engl J Med 1972; 286 (18): 988-92
21. Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med 1966; 118 (4): 304-9
22. Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988; 260 (20): 3025-9 (Pubitemid 19003118)
23. Dole VP, Nyswander ME, Warner A. Successful treatment of 750 criminal addicts. JAMA 1968; 206 (12): 2708-11
24. Strain EC, Stitzer ML, Liebson IA, et al. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119 (1): 23-7 (Pubitemid 23177293)
25. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991
26. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; (3): CD002209
27. Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Substance Abuse Treat 2003; 25 (3): 125-34 (Pubitemid 37518373)
28. Strain EC, Bigelow GE, Liebson IA, et al. Moderate-vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281 (11): 1000-5 (Pubitemid 29143891)
29. Donny EC, Brasser SM, Bigelow GE, et al. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioiddependent volunteers. Addiction 2005; 100 (10): 1496-509 (Pubitemid 41442319)
30. Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2009; 32 (2): 131-9
31. Kim TW, Alford DP, Malabanan A, et al. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85 (3): 258-62 (Pubitemid 44666285)
32. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150 (6): 387-95
33. Gourevitch MN. First do no harm . reduction? Ann Intern Med 2009; 150 (6): 417-8
34. Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104 (6): 993-9
35. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Populationbased pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95 (12): 1771-83 (Pubitemid 32055815)
36. Lucas AC, Bermejo AM, Tabernero MJ, et al. Influence of concomitant drugs on methadone elimination half-life in patients under a maintenance treatment. Addict Biol 2001; 6 (2): 171-6 (Pubitemid 32436732)
37. Eap CB, Bourquin M, Martin J, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61 (1): 47-54
38. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19 (1): 4-16
39. Bickel WK,Amass L. Buprenorphine treatment of opioid dependence: a review. Exper Clin Psychopharmacol 1995; 3: 477-89
40. Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93 (4): 475-86 (Pubitemid 28188067)
41. Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310, Title XXXV, sections 3501-3502 (2000)
42. Vicknasingam B, Mazlan M, Schottenfeld RS, et al. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010; 111 (1-2): 44-9
43. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88 (1): 75-8 (Pubitemid 46400304)
44. Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology 1999; 141 (1): 37-46 (Pubitemid 29193293)
45. Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004; 43 (5): 329-40 (Pubitemid 38534755)
46. Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4 : 1 ratio for treatment? Drug Alcohol Depend 2003; 70 (2 Suppl.): S29-37 (Pubitemid 36556058)
47. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers [published erratum appears in Addiction 2010 Jul; 105 (7): 1332]. Addiction 2010; 105 (4): 709-18
48. Fudala PJ, Jaffe JH, Dax EM, et al. Use of buprenorphine in the treatment of opioid addiction, II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47 (4): 525-34 (Pubitemid 20151479)
49. Amass L, Bickel WK, Higgins ST, et al. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54 (17): 1215-28 (Pubitemid 24107403)
50. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267 (20): 2750-5
51. Amass L, Kamien JB, Branstetter SA. A controlled comparison of the buprenorphine-naloxone tablet and methadone for opioid maintenance treatment: interim results. In: Harris L, editor. Problems of drug dependence 1999 (NIDA research monograph). Rockville (MD): National Institute on Drug Abuse, 2001
52. Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151 (7): 1025-30 (Pubitemid 24208639)
53. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996; 16 (1): 58-67
54. Sohler NL, Li X, Kunins HV, et al. Home-versus officebased buprenorphine inductions for opioid-dependent patients. J Substance Abuse Treat 2010; 38 (2): 153-9
55. Tetrault JM, Sullivan LE, Fiellin DA. Medical management. In: Renner JA, Levonuis P, editors. Handbook of officebased buprenorphine treatment of opioid dependence. Washington, DC: American Psychiatric Publishing, Inc., 2011
56. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9 (3): 265-9
57. Bruce RD, Altice FL. Case series on the safe use of buprenorphine/ naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007; 33 (6): 869-74 (Pubitemid 350125776)
58. Vergara-Rodriguez P, Tozzi M, Botsko M, et al., BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/ naloxone in HIV-infected opioid-dependent patients. J Acquire Immune Defic Syndr 2011; 56 Suppl. 1: S62-7
59. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167 (22): 2469-75 (Pubitemid 350254906)
60. Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93 (9): 1385-92 (Pubitemid 28430045)
61. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91 (2-3): 269-78 (Pubitemid 47539730)
62. Deamer RL, Wilson DR, Clark DS, et al. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20 (4): 7-14 (Pubitemid 33095745)
63. Ritter AJ, Lintzeris N, Clark N, et al. A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 2003; 98 (11): 1605-13 (Pubitemid 37373859)
64. Wolstein J, Gastpar M, Finkbeiner T, et al. A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 2009; 42 (1): 1-8
65. Wieneke H, Conrads H, Wolstein J, et al. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation: results from a controlled clinical trial. Eur J Med Res 2009; 14 (1): 7-12
66. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr 1995; 150: 37-52
67. KleberHD.Naltrexone. J Subst Abuse Treat 1985; 2 (2): 117-22 (Pubitemid 16207722)
68. Warner EA, Kosten TR, O'Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am 1997; 81 (4): 909-25 (Pubitemid 27298934)
69. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011; (4): CD001333
70. Fram DH, Marmo J, Holden R. Naltrexone treatment: the problem of patient acceptance. J Subst Abuse Treat 1989; 6 (2): 119-22 (Pubitemid 19150038)
71. Greenstein RA, Arndt IC, McLellan AT, et al. Naltrexone: a clinical perspective. J Clin Psychiatry 1984; 45 (9 Pt 2): 25-8 (Pubitemid 14030107)
72. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984; 45 (9 Pt 2): 46-8 (Pubitemid 14030111)
73. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58 (8): 755-61 (Pubitemid 32717799)
74. SullivanMA,Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006; 15 (2): 150-9
75. Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 1984; 10 (2): 249-66 (Pubitemid 14084504)
76. McCann MJ, Miotto K, Rawson RA, et al. Outpatient nonopioid detoxification for opioid withdrawal: who is likely to benefit? Am J Addict 1997; 6 (3): 218-23 (Pubitemid 27356004)
77. Farren CK, O'Malley SS, Rounsaville B. New treatments for opiate dependence. In: Stine SM, Kosten TR, editors. The Guilford substance abuse series. New York: Guilford Press, 1997: 104-23
78. Thomson Reuters (Healthcare) Inc. Micromedex healthcare series. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2009
79. Thomson Reuters (Healthcare) Inc. DRUGDEx system 2009. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2009
80. Tetrault JM, Tate JP,McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness inHIV-infected patients receiving naltrexone. Alcohol Clin Exper Res. Epub 2011 Jul 28
81. Lobmaier P, Kornør H, Kunøe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD006140
82. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustainedrelease naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63 (2): 210-8 (Pubitemid 43213883)
83. Krupitsky E, Nunes EV, Ling W, et al. Injectable extendedrelease naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377 (9776): 1506-13
84. Kunøe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194 (6): 541-6
85. Kunøe N, Lobmaier P, Vederhus JK, et al. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend 2010; 111 (1-2): 166-9
86. Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010; 23 (3): 210-4
87. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304 (14): 1576-83
88. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; (8): CD003410